Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Palisade Bio, Inc. (NASDAQ:PALI)*

Organization & Developments: Palisade Bio

Parents

2021: Palisade Bio: Guarding Intestinal Integrity
2022: With cash evaporating quickly, Palisade Bio cuts staff to save money and focus on sole GI med
Palisade Bio, Inc. (NASDAQ:PALI) is a clinical stage biopharmaceutical company developing innovative oral therapies to target acute and chronic diseases resulting from inflammation and tissue damage, associated with the digestive-enzyme (protease) leak due to breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract.